Business Wire

Alpine Investors Finalizes Oversubscribed Ninth Fund at Hard Cap of $4.5 Billion in Capital Commitments


Alpine Investors (“Alpine”), a Certified B Corp people-driven private equity firm committed to building enduring software and services companies, announced today the completion of fundraising for Alpine Investors IX (“Fund IX”), reaching the fund’s hard cap of $4.5 billion in limited partner capital commitments.

Fundraising for Fund IX launched with a target of $3.75 billion and was oversubscribed. Fund IX is double the size of Alpine’s previous fund, Alpine Investors VIII, which was similarly oversubscribed and closed at its hard cap of $2.25 billion of limited partner commitments in August 2021.

Fund IX received limited partner commitments from a diversified investor base of returning and new investors from the U.S., Europe, Asia, and the Middle East. Alpine plans to invest the capital for Fund IX in control buyouts of software and services businesses with total enterprise values of up to $1 billion and focus on add-on acquisitions for high-performing platform investments.

“We are thrilled with this outcome, particularly in a very challenging fundraising environment,” said Graham Weaver, Founder and CEO of Alpine Investors. “We started Alpine 22 years ago with the thesis that the secret to building companies was hiring and training world-class leaders. It is incredibly satisfying to think that treating people well and giving them opportunities to be their best selves at work has been the formula for our investing success. We’re extremely grateful to have a wonderful group of like-minded investors and partners who have supported us along the way, and we are excited to continue this amazing journey together with them.”

Alpine has been active in recent years across its software and services specialties through buyouts as well as the launch of several prominent platforms. Notable investments from the last year include:

  • The successful expansion of ASG, Alpine’s software business that buys vertical SaaS companies and builds them into market leaders, with more than 50 acquisitions since inception;
  • The announcement of AlpineX’s professional education vertical, Axcel Learning, and its water services vertical, Axia Water;
  • The formation of predictis, a data-enabled software platform launched in conjunction with the acquisition of AirDNA;
  • The establishment of the Trilon Group, an engineering services platform, with 15 acquisitions including Alta Planning + Design, Inc., a globally-renowned active mobility and sustainability consulting firm;
  • The acquisition of FEV Tutor, a K-12 market leading research and evidence-based online tutoring platform;
  • The acquisition of Medusind, a leading provider of revenue cycle management services to the healthcare industry; and
  • The formation of Ascend, a platform that partners with entrepreneurial CPAs, through its acquisition of Opsahl Dawson.

“We are grateful for the continued partnership from so many long-standing investors in Alpine, and we are excited by the significant presence of new partners across the globe that chose to participate in Fund IX,” said April Smith, Head of Investor Relations and Fundraising, Alpine Investors. “The makeup of Fund IX is the most global of any of our funds to date, demonstrating our expanding reach, and the robust market interest we generated underscores the increasing awareness of our value proposition for investors.”

Founded in 2001, Alpine Investors has over $15 billion in assets under management with more than 20,000 employees within its portfolio companies.1 The firm is known for its PeopleFirst operating philosophy and its executive talent programs, which recruit and develop MBA graduates into CEOs and other executive-level roles. Originating with its CEO-in-Training and CEO-in-Residence programs, Alpine employs over 110 CEOs and executive-level roles within its portfolio companies through these talent programs.

Evercore Inc. served as placement agent for the fund and Kirkland & Ellis served as legal counsel to Alpine.

About Alpine Investors

Alpine Investors is a people-driven private equity firm committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in the software and services industries. Alpine’s PeopleFirst strategy includes a talent program that allows Alpine to bring leadership to situations where additional or new management is needed post-transaction. Alpine has over $15 billion in assets under management as of March 31, 2023 and has three offices in San Francisco, New York, and Salt Lake City.1 For more information, visit and for full disclaimers including, but not limited to, third-party reviews and Alpine Operations Group.

1 Pro forma for additional Fund IX commitments raised as of June 30, 2023 and fair market value as of March 31, 2023.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Audrey Harris
Head of Marketing

Sarah Braunstein

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an

Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release

GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with

Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release

Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom